Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimo Dietrich

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapyOliver Hartmann, Frédérique Spyratos, Nadia Harbeck, et al.
Ebiomedicine|October 20, 2019
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signatureVerena Sailer, Ulrike Sailer, Emma Grace Bawden, et al.
Clinical Chemistry|July 21, 2023
Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma PatientsDimo Dietrich, Simone Weider, Luka de Vos, et al.
Translational Oncology|December 23, 2015
Prognostic Significance and Functional Role of CEP57 in Prostate CancerJosef Mang, Nina Korzeniewski, Dimo Dietrich, et al.
Biomarker Research|May 31, 2023
ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockadeDamian J Ralser, Emmanuelle Herr, Luka de Vos, et al.
BMC Cancer|November 5, 2010
SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspiratesBernd Schmidt, Volker Liebenberg, Dimo Dietrich, et al.
Human Mutation|September 15, 2018
Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trialKonstantin Weber-Lassalle, Philipp Harter, Jan Hauke, et al.
Clinical Chemistry|May 19, 2017
Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort StudyAndreas Schröck, Annette Leisse, Luka de Vos, et al.
Clinical Epigenetics|July 6, 2023
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinomaFriederike Hoffmann, Alina Franzen, Luka de Vos, et al.
Clinical Epigenetics|June 27, 2020
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanomaFriederike Hoffmann, Romina Zarbl, Dennis Niebel, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapyOliver Hartmann, Frédérique Spyratos, Nadia Harbeck, et al.
Ebiomedicine|October 20, 2019
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signatureVerena Sailer, Ulrike Sailer, Emma Grace Bawden, et al.
Clinical Chemistry|July 21, 2023
Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma PatientsDimo Dietrich, Simone Weider, Luka de Vos, et al.
Translational Oncology|December 23, 2015
Prognostic Significance and Functional Role of CEP57 in Prostate CancerJosef Mang, Nina Korzeniewski, Dimo Dietrich, et al.
Biomarker Research|May 31, 2023
ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockadeDamian J Ralser, Emmanuelle Herr, Luka de Vos, et al.
BMC Cancer|November 5, 2010
SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspiratesBernd Schmidt, Volker Liebenberg, Dimo Dietrich, et al.
Human Mutation|September 15, 2018
Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trialKonstantin Weber-Lassalle, Philipp Harter, Jan Hauke, et al.
Clinical Chemistry|May 19, 2017
Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort StudyAndreas Schröck, Annette Leisse, Luka de Vos, et al.
Clinical Epigenetics|July 6, 2023
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinomaFriederike Hoffmann, Alina Franzen, Luka de Vos, et al.
Clinical Epigenetics|June 27, 2020
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanomaFriederike Hoffmann, Romina Zarbl, Dennis Niebel, et al.
Pageof 12